文献速递肿瘤 PET/CT核素与放射性配体治疗

前列腺癌治疗后严重钙化:双显像剂PET/CT假阳性警示

Severe Post-treatment Calcification for Prostate Cancer With Dual ¹⁸F-FDG and ⁶⁸Ga-PSMA Avidity on PET/CT.
PubMed 文献 · Clin Nucl Med · 2026-03-23

一例66岁前列腺腺癌患者经放疗和内分泌治疗后,¹⁸F-FDG与⁶⁸Ga-PSMA PET/CT均显示明显放射性摄取,疑为复发;后续经尿道前列腺切除病理活检仅见慢性炎症伴局灶坏死和钙化,提示这两种显像在非恶性病变中存在假阳性风险。

要点

  • 前列腺癌治疗后钙化性炎症可致FDG与PSMA PET/CT双假阳性。
  • 双显像剂高摄取不能单独确诊复发,需病理验证。
  • 非恶性病变是PET/CT判读的重要鉴别点。

核心结论

  • 前列腺癌治疗后非恶性慢性炎症伴钙化可导致¹⁸F-FDG和⁶⁸Ga-PSMA PET/CT均出现明显摄取,需警惕假阳性。

研究设计与样本

  • 单例病例报告:66岁前列腺腺癌患者,接受放疗和内分泌治疗后行¹⁸F-FDG与⁶⁸Ga-PSMA PET/CT,后续经尿道前列腺切除并同期病理活检。

主要发现

  • 两种PET/CT显像均显示明显放射性示踪剂摄取,最初怀疑疾病复发。
  • 病理活检确诊仅为慢性炎症伴局灶坏死和钙化,未见恶性证据。

临床怎么用

  • 对前列腺癌治疗后患者,FDG或PSMA PET/CT高摄取病灶应结合临床及病理,避免仅凭影像诊断复发。

局限性

  • 单例病例报告,结论外推受限;原文未报告定量摄取参数、随访时长及更大样本验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A 66-year-old man with a history of prostate adenocarcinoma treated with radiotherapy and endocrine therapy underwent 18 F-FDG and 68 Ga-PSMA PET/CT. Both scans showed marked radiotracer uptake, raising suspicion for disease recurrence. However, subsequent transurethral resection of the prostate was performed for treatment with concurrent pathologic biopsy, confirmed only chronic inflammation accompanied by focal necrosis and calcification, emphasizing the false-positive risk of these modalities in nonmalignant conditions.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Du B, Liu G, Liu Y, et al. Severe Post-treatment Calcification for Prostate Cancer With Dual ¹⁸F-FDG and ⁶⁸Ga-PSMA Avidity on PET/CT. Clin Nucl Med. 2026. PMID: 41940837. doi:10.1097/RLU.0000000000006416

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。